Experience with angiotensin II antagonists in hypertensive patients.

Details

Serval ID
serval:BIB_5823
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
Experience with angiotensin II antagonists in hypertensive patients.
Title of the conference
Baker-Medical-Research-Institutes Annual Symposium
Author(s)
Waeber B., Burnier M., Nussberger J., Brunner H.R.
Address
Melbourne, Australia, December 08-09, 1995
ISSN
0305-1870
Publication state
Published
Issued date
1996
Volume
23
Series
Clinical and Experimental Pharmacology and Physiology
Pages
142-146
Language
english
Notes
1. The availability of orally active specific angiotensin receptor antagonists (ATI antagonists) has opened new therapeutic choices and provided probes to test the specific role of the renin-angiotensin system in the pathogenesis of cardiovascular disease.
2. The data available so far suggest that the antihypertensive efficacy of angiotensin receptor antagonists is comparable to that of angiotensin-converting enzyme (ACE) inhibitors, This provides further evidence that this latter class of drugs exerts its effect mainly through blockade of the renin-angiotensin enzymatic cascade; As expected, the association of a diuretic exerts an equally strong additive effect to the antihypertensive efficacy of both classes of drugs,
3. The most common side effect of ACE inhibitors, dry cough, does not occur with AT(1) antagonists, which confirms the long-held view that this untoward effect of the ACE inhibitors is due to renin-angiotensin-independent mechanisms.
4. Long-term studies with morbidity/mortality outcome results are needed, before a definite position can be assigned to this newcomer in the orchestra of modern antihypertensive drugs, Notwithstanding, this new class of agents already represents an exciting new addition to our therapeutic armamentarium.
Keywords
AT(1) Receptor Antagonists, Combination Therapy, Efficacy, Irbesartan, Losartan, Renal Effects, Side Effects, TCV-116 Tolerability, Receptor Antagonist, Healthy-Subjects, Losartan Potassium, Blood-Pressure, Blockade, Hydrochlorothiazide, Volunteers, DUP-753, Renin
Pubmed
Create date
19/11/2007 13:42
Last modification date
27/11/2019 7:19
Usage data